Recent Articles

Neurogene announced that NGN-401 received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for the treatment of Rett syndrome. The designation was based on preliminary clinical evidence from the ongoing Phase 1/2 clinical trial with NGN-401 that shows potential to ...

Taysha reports financial results as well as updates on their pediatric and adult clinical trials.

Neurogene announced initial safety and tolerability data from its Rett gene therapy clinical. NGN-401 was generally well-tolerated by all three patients dosed, with follow-up of approximately 9, 6 and 3 months post-dosing. These data were presented during the American Society of Gene and Cell ...

Taysha announced the FDA has granted RMAT designation to TSHA-102. Companies receiving RMAT designation can benefit from increased interactions with the FDA with the goal of expediting drug development.